Leerink Partners’ Post

Have you subscribed to the Argenica Therapeutics Investor Hub? Whether you're a current investor, future investor or you're just interested in learning more about the commercialisation of ARG-007, joining our Investor Hubs ensure you never miss an important piece of Company news. When you subscribe, you receive the following, direct to your inbox: ➡ ASX announcements ➡ Updates on news coverage relating to Argenica ➡ Important updates and relevant company information Learn more or join today: https://bit.ly/3UO305v #ASX #AGN #InvestorRelations #StrokeAwareness #InvestorNews #ARG007

Apogee Therapeutics ( $APGE ) social hype OVER HYPED. Current chance of bankruptcy is under 6%: Debt can assist Apogee Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Apogee Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Apogee Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Apogee to invest in growth at high rates of return. When we think about Apogee Therapeutics' use of debt, we should always consider it together with cash and equity. Apogee Therapeutics preserves 8.08 x of book value per share. Apogee Therapeutics is selling for under 34.91. That is -0.57% down. Opened at 35.11. https://lnkd.in/g5BZDraG #trading #ideas #stocks

Apogee Therapeutics ( $APGE ) social hype OVER HYPED. odds of financial distress is under 1%.: Debt can assist Apogee Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Apogee Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Apogee Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Apogee to invest in growth at high rates of return. When we think about Apogee Therapeutics' use of debt, we should always consider it together with cash and equity. Apogee Therapeutics makes 75.00 % probability of bankruptcy. Apogee Therapeutics is selling for under 34.90. That is 0.43 percent increase. Day Low was 34.69. https://lnkd.in/g5BZDraG #hotstocks #investing #trading

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances #stockmarket #stocks #investing #businessnews #trading #daytrading #earnings #financialresults #clinicaltrial

🎉Congratulations from Checkmate Equity🎉 💼Company: Attovia Therapeutics💰#Funding: $105Million⚡Round: Series B 👥Investors: Goldman Sachs Alternatives, Cormorant Asset Management, LP, Nextech Ventures, Redmile Group, EcoR1 Capital, LLC, Marshall Wace, and Logos Capital. Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated diseases. The company leverages ATTOBODY™, a biparatopic biologics platform, to generate binders that offer stronger efficacy and a broader universe of druggable epitopes compared to traditional approaches. 🚀OFFLOAD YOUR CAP TABLE MANAGEMENT TASKS TODAY🎉 Checkmate Equity is a trusted Carta partner with experience managing over 2,000 #captables. Our expertise ensures compliance, accuracy, and timely updates for your cap table. With a dedicated Equity Administrator, we streamline the process, ensuring rapid updates. 🚀 Tao Fu and Zaneta Odrowaz, let me know if you need assistance with the adjustments to your Cap Table. 📊

My latest article on biotech investing has been published! The article covers TG Therapeutics and the disease-modifying therapy (DMT) market for relapsing forms of multiple sclerosis. https://lnkd.in/ev4fsPGT

Esperion Therapeutics (NASDAQ: ESPR) Stock Jumps on Upbeat Q1 Financial Report https://lnkd.in/dgvfr3rW $ESPR #Esperion #NASDAQ #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert

Our team at Lowenstein Sandler LLP advised on the private placement of $100M common stock of Context Therapeutics for Piper Sandler. Read more about this transaction and our role in the process. #corporatelaw #lawfirms #securitieslaw #capitalmarkets #lawyers

𝗔𝗿𝗿𝗶𝗩𝗲𝗻𝘁 𝗼𝘂𝘁𝗹𝗶𝗻𝗲𝘀 𝗽𝗹𝗮𝗻𝘀 𝗳𝗼𝗿 $𝟭𝟯𝟱𝗠 𝗜𝗣𝗢 𝗶𝗻 𝘀𝗲𝗰𝗼𝗻𝗱 𝗯𝗶𝗼𝘁𝗲𝗰𝗵 𝗹𝗶𝘀𝘁𝗶𝗻𝗴 𝗼𝗳 𝟮𝟬𝟮𝟰 ArriVent Biopharma, a Pennsylvania drugmaker developing a China-approved cancer treatment for the US and other geographies, plans to raise net proceeds of about $135 million in its Nasdaq listing. It would be the second biotech IPO of the year after CG Oncology last week outlined its pitch for a $181 million Wall Street debut. ArriVent plans on selling 8.33 million shares in its IPO and expects to price at $17 to $19 per share $AVBP, per a Monday morning SEC filing. Biotechs tend to go public within a week of penciling in their price range. Zhengbin (Bing) Yao, CEO pictured. More below: https://lnkd.in/dp6BXWbw

Our team at Lowenstein Sandler LLP advised on the private placement of $100M common stock of Context Therapeutics for Piper Sandler. Read more about this transaction and our role in the process. #corporatelaw #lawfirms #securitieslaw #capitalmarkets #lawyers